Question 1

What’s the financial overview for Halozyme Therapeutics, Inc.?

Accepted Answer

Halozyme Therapeutics, Inc.’s market cap stands at $0.007 trillion right now. The company’s trailing twelve-month earnings per share EPS is $3.76, with a dividend yield of N/A%. Their next earnings report is set for January 29, 2025, and the estimated EPS for that period is $1.61. You can also check out summaries of their income statement, balance sheet, and cash flow details for a fuller picture of their financials.

Question 2

How can I analyze historical data?

Accepted Answer

To analyze historical data with AI tools, apply the date range filter above the table to focus on a specific period. The table displays daily open, high, low, close prices, and volume, enabling you to spot trends and patterns. Use these insights to make informed decisions based on historical performance.

Question 3

What does Halozyme Therapeutics, Inc. Stock ROE tell us?

Accepted Answer

Halozyme Therapeutics, Inc. stock ROE shows positive market sentiment. A higher ROE means the company’s management is doing a better job at using equity financing to drive income and growth. It’s a handy metric for comparing how a company stacks up against its competitors or the broader market.

Question 4

What do Analysts say about Halozyme Therapeutics, Inc.?

Accepted Answer

3 number of Analysts recommended buying Halozyme Therapeutics, Inc. the stock and 0 analysts recommended selling the stock.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024
Revenue	$298.008M	$290.08M	$231.35M	$195.88M
Cost of Revenue	$42.05M	$49.43M	$57.37M	$46.09M
Gross Profit	$255.95M	$240.66M	$173.98M	$149.79M
Gross Profit Ratio	$0.86	$0.83	$0.75	$0.76
R&D Expenses	$20.44M	$18.46M	$21.04M	$19.11M
SG&A Expenses	$42.25M	$41.24M	$35.71M	$35.13M
Operating Expenses	$80.45M	$77.46M	$56.75M	$54.24M
Total Costs & Expenses	$122.51M	$126.89M	$114.12M	$100.34M
Interest Income	$0.00	$0.00	$0.00	$0.00
Interest Expense	$4.54M	$4.52M	$4.52M	$4.51M
Depreciation & Amortization	$20.41M	$20.36M	$20.36M	$20.21M
EBITDA	$203.17M	$190.03M	$137.60M	$115.75M
EBITDA Ratio	$0.68	$0.66	$0.59	$0.59
Operating Income	$175.50M	$163.20M	$117.23M	$95.54M
Operating Income Ratio	$0.59	$0.56	$0.51	$0.49
Other Income/Expenses (Net)	$2.71M	$1.95M	$508000.00	$486000.00
Income Before Tax	$178.21M	$165.15M	$117.74M	$96.03M
Income Before Tax Ratio	$0.60	$0.57	$0.51	$0.49
Income Tax Expense	$41.20M	$28.14M	$24.50M	$19.20M
Net Income	$137.01M	$137.01M	$93.25M	$76.82M
Net Income Ratio	$0.46	$0.47	$0.40	$0.39
EPS	$1.08	$1.08	$0.73	$0.61
Diluted EPS	$1.06	$1.05	$0.72	$0.60
Weighted Avg Shares Outstanding	$126.41M	$126.85M	$127.12M	$126.94M
Weighted Avg Shares Outstanding (Diluted)	$128.98M	$130.13M	$129.22M	$128.89M

Halozyme Therapeutics, Inc.